The increased survival of patients with GBM in the past few decades is primarily owing to new biomarkers and treatments derived from biomarkers, such as isocitrate dehydrogenase (IDH), epidermal growth factor receptor (EGFR) and O-6-methylguanine-DNA methyltransferase (MGMT). The gene discussed is EGFR; the disease is glioblastoma.